期刊文献+

足叶乙甙联合重组人粒细胞集落刺激因子动员自体外周血干细胞的临床研究 被引量:2

Mobilization of autologous peripheral blood stem cells with etoposide and recombinant human granulocyte colony stimulating factor in malignant tumor patients
原文传递
导出
摘要 目的 观察足叶乙甙 (Vp 16 )联合重组人粒细胞集落刺激因子 (rhG CSF)对恶性实体瘤患者自体外周血造血干细胞 (APBSC)的动员效果 ,并寻找Vp 16合适的给药剂量。方法 按照入组的先后顺序 ,将 30例患者随机分成A、B两组 ,每组 15例。A组Vp 16的给药剂量为 10 0 0mg/m2 ,B组为15 0 0mg/m2 。白细胞 (WBC)降至最低点时开始皮下注射rhG CSF 30 0 μg/d ,直至采集结束前一天。WBC恢复到 5 .0× 10 9/L以上时开始连日采集APBSC ,当累计采集的单个核细胞 (MNC)≥ 5× 10 8/kg或CD34+ 细胞≥ 2× 10 6/kg时停止采集。结果 Vp 16给药后 ,A、B两组患者外周血中WBC和中性粒细胞绝对值 (ANC)的最低值及最低值出现的时间 ,差异均无显著性。两组rhG CSF给药的开始时间和给药次数、APBSC采集的开始时间和采集次数差异均无显著性 ;在APBSC采集时的循环血量、血流速度和采集时间相同的情况下 ,每次APBSC采集的细胞数量和总量差异亦无显著性 ,B组Vp 16引起的某些毒副反应略重于A组 ,但两组间差异无显著性。结论 Vp 16联合rhG CSF是一种安全、高效的APBSC动员方法 ,15 0 0mg/m2 与 10 0 0g/m2 的Vp 16均可获得满意的APBSC动员采集效果。 Objective To observe the combined effect of etoposide (Vp 16) and recombinant human granulocyte colony stimulating factor ( rhG CSF) on mobilization of autologous peripheral blood stem cells (APBSC) in malignant tumor patients and find out the suitable dose of Vp 16. Methods Thirty patients were randomly divided into two groups, 15 in each group. In group A, Vp 16 1000 mg/m 2 was injected intravenously in six divided doses, for 2 hours every 12 hours on day 1, 2 and 3. In group B, Vp 16 1500 mg/m 2 was injected intravenously in six divided doses for 3 hours every 12 hours on day 1, 2 and 3. rhG CSF was given as a single daily injection subcutanously at the dose of 300 μg·body -1 ·day -1 from the day of the nadir of white blood cell(WBC) to the day before the end of APBCS harvest. APBSC harvest started when WBC ≥5.0×10 9/L and finished when accumulated mononuclear cells (MNC) ≥5×10 8/kg or CD34 + cells ≥2×10 6/kg. ResultsThere was no significant difference between the time of nadir, nadir of WBC, absolute neutrophil count (ANC), the beginning time and continuous time of rhG CSF given, the beginning time and continuous time of APBSC harvest. When the blood volume, flow rate and continuous time of apheresis were similar in each apheresis in the two groups, the number of APBSC in each harvest and total number of APBSC were also not significantly different between the two groups. The side effects induced by Vp 16 were also not significant different between the two groups. Conclusion Vp 16 combined with rhG CSF is a safe and highly effective method for APBSC mobilization, 1000 mg/m 2 and 1500 mg/m 2 of Vp 16 possess similar efficiency and side effects for APBSC mobilization.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2004年第6期360-363,共4页 Chinese Journal of Oncology
基金 国家"九五"攻关基金资助项目 (96 90 6 0 1 12 ) 国家教委高等院校博士学科点专项基金资助项目 (2 0 0 10 0 2 3 0 18)
关键词 足叶乙甙 人粒细胞集落刺激因子 外周血干细胞 RHG-CSF APBSC Etoposide Colony-stimulating factors, recombinant Autologous peripheral blood stem cell mobilization Stem cell transplantation
  • 相关文献

参考文献8

二级参考文献27

  • 1GratwohlA PasswegJ BaldomeroH et al.Blood and marrow transplantation activity in Europe 1997[J].European Group for Blood and Marrow Transplantation ( EBMT). Bone Marrow Transplant,1999,24:231-245.
  • 2Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between con-ventional salvage therapy and high-dose therapy with autografting for re-current or refractory Hodgkin's disease. Blood, 1997, 89:814-822.
  • 3Nademanee A, Molina A, Fung H, et al. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-riskadvanced-stage Hodgkin's disease during first partial or complete remission. Biol Blood Marrow Transplant, 1999, 5:292-298.
  • 4Delain M, Cartron G, Bout M, et al. Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome. Leuk Lymphoma,1999, 34: 305-313.
  • 5Philip T, Gomez F, Guglielmi C, et al. Long-term outcome of the relapse non-Hodgkin's lymphoma (NHL) patients included in the PARMA trial: incidence of late relapse, long-term toxicity and impact of the international prognostic index (IPI) at relapse. Proc Am Soc Clin Oncol,1998, 18: abstr 16.
  • 6Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplantation Registry. J Clin Oncol, 2001, 19: 406-13.
  • 7Haiotun C, Lepage E, Gisselbrecht C, et al. Survival benefit of highdose therapy in poor-risk aggressive non-Hodgkin' s lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol, 2000, 18: 3025-3030.
  • 8Gimmi AM, Bregni M, Siena S, et al. High-dose chemotherapy and autololgous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med, 1997, 336:1290-1297.
  • 9Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse nonHodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol,1998, 16: 2796-2802.
  • 10Bouabdallah R, Xerri L, Bardou V-J, et al. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol,1998,9: 619-625.

共引文献34

同被引文献64

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部